| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Propargyl-PEG4-bromide does not have a biological target. It is a chemical linker used for bioconjugation. Its utility lies in its two reactive functional groups: the bromide for nucleophilic substitution reactions and the propargyl group for copper-catalyzed azide-alkyne cycloaddition (CuAAC) click chemistry. It is used to conjugate drugs, proteins, or other molecules.
|
|---|---|
| ln Vitro |
Two distinct ligands, one for the E3 ubiquitin ligase and the other for the target protein, are present in PROTAC and are joined by a linker. PROTAC targets and selectively degrades target proteins by means of the intracellular ubiquitin-proteasome system. An ADC cytotoxin is connected to an antibody by use of an ADC linker to form an ADC.
Propargyl-PEG4-bromide does not exhibit direct in vitro biological activity. Its activity is defined by its chemical reactivity. It is used to functionalize molecules for biological studies. The bromide group can be displaced by nucleophiles to form stable bonds, while the alkyne group allows for specific and efficient conjugation via click chemistry. |
| ln Vivo |
Propargyl-PEG4-bromide is not a therapeutic agent and does not have direct in vivo biological activity. Its in vivo behavior is determined by the conjugates it helps create. When conjugated to drugs, the PEG component improves solubility, stability, and circulation time. The linker is not administered as a standalone compound.
|
| Enzyme Assay |
In vitro conjugation protocols for Propargyl-PEG4-bromide involve reacting the bromide with a nucleophile (e.g., a thiol or amine) and the alkyne with an azide via CuAAC click chemistry. The reaction can be performed in aqueous buffers or organic solvents. The progress of the reaction is monitored by HPLC or mass spectrometry.
|
| Cell Assay |
Cell-based assays using Propargyl-PEG4-bromide typically involve treating cells with conjugates synthesized using this linker, rather than the linker itself. For example, cells are treated with drug conjugates, and cellular uptake and cytotoxicity are assessed. The linker itself is not tested in cell-based assays.
|
| Animal Protocol |
In vivo animal studies involving Propargyl-PEG4-bromide are conducted using the final conjugates, rather than the linker alone. Typical protocols involve administering the conjugate to mice via intravenous injection. Pharmacokinetic studies assess the circulation time and tissue distribution of the conjugate.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of Propargyl-PEG4-bromide are determined by the conjugates it forms. The PEG spacer improves aqueous solubility, reduces renal clearance, and extends circulation half-life. The linker itself is not administered as a standalone compound.
|
| Toxicity/Toxicokinetics |
Propargyl-PEG4-bromide is considered a laboratory chemical with low inherent toxicity. The PEG component is biocompatible. The compound is not intended for human or veterinary therapeutic use. Standard safety precautions should be followed. Storage at -20°C is recommended.
|
| References | |
| Additional Infomation |
Propargyl-PEG4-bromide is a heterobifunctional PEG linker for ADC and PROTAC synthesis. It contains a bromide for nucleophilic reactions and a propargyl group for click chemistry. It is for research use only.
|
| Molecular Formula |
C11H19BRO4
|
|---|---|
| Molecular Weight |
295.170163393021
|
| Exact Mass |
294.046
|
| CAS # |
1308299-09-3
|
| PubChem CID |
91809458
|
| Appearance |
Light yellow to yellow liquid
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
334.3±32.0 °C at 760 mmHg
|
| Flash Point |
135.7±23.6 °C
|
| Vapour Pressure |
0.0±0.7 mmHg at 25°C
|
| Index of Refraction |
1.476
|
| LogP |
0.37
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
16
|
| Complexity |
178
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
BrCCOCCOCCOCCOCC#C
|
| InChi Key |
BITLDNUKJCDASJ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C11H19BrO4/c1-2-4-13-6-8-15-10-11-16-9-7-14-5-3-12/h1H,3-11H2
|
| Chemical Name |
3-[2-[2-[2-(2-bromoethoxy)ethoxy]ethoxy]ethoxy]prop-1-yne
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3879 mL | 16.9394 mL | 33.8788 mL | |
| 5 mM | 0.6776 mL | 3.3879 mL | 6.7758 mL | |
| 10 mM | 0.3388 mL | 1.6939 mL | 3.3879 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
